VPH is an international community driving the adoption of in silico medicine by connecting scientists, industry, clinicians, patients, healthcare providers, regulators, and policymakers for a better and more efficient healthcare.
Countries involved
Institutions involved
Members
Discover more
Office of Health Economics's report highlights the potential health, economic and industry benefits of investing in the UK Centre of Excellence for In-Silico Regulatory Science and Innovation, provided adequate funding is secured.
The UK regulator plans new guidance and regulatory frameworks to advance computational evidence, digital twins and synthetic data in medicines development and clinical trials.
The HPP Thematic Network on "Building Responsible Ecosystem Solutions: AI and Virtual Human Twins in Healthcare" is entering its final phase and invites stakeholders to contribute their feedback to the draft Joint Statement.
